VKTX - Viking Therapeutics, Inc.
9.33 +0.02 (0.21%)
After hours: 5:43PM EST
| Previous Close | 9.81 |
| Open | 10.01 |
| Bid | 9.27 x 900 |
| Ask | 9.39 x 3100 |
| Day's Range | 9.30 - 10.05 |
| 52 Week Range | 3.66 - 24.00 |
| Volume | 2,355,908 |
| Avg. Volume | 4,730,831 |
| Market Cap | 665.292M |
| Beta (3Y Monthly) | 4.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.44 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.79 |
- Insider Monkey•2 days ago
Hedge Funds Are Betting On Viking Therapeutics, Inc. (VKTX)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and […]
- Motley Fool•3 days ago
Why Viking Therapeutics Stock Continued to Slide in November
Despite a couple of positive developments, Viking's stock continued to move lower last month. Here's why.
- Motley Fool•5 days ago
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
Impressive results from a potential competitor took the shine off this biotech's experimental NASH treatment.
- GlobeNewswire•10 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within The Trade Desk, United Rentals, ServiceMaster Global, Talend S.A, Viking Therapeutics, and SEACOR — New Research Emphasizes Economic Growth
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- ACCESSWIRE•16 days ago
Growth Opportunities in Stocks Coming Off of Bottoms
HENDERSON, NV / ACCESSWIRE / November 27, 2018 / With the market in a bit of a swoon, many companies with positive 3 rd quarter announcements have not yet seen them baked into the share price properly. ...
- Benzinga•24 days ago
Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade
Between Viking's lead asset VK2809 and Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)'s MGL-3196 — both of which are thyroid hormone beta receptor agonists — VK2809 is more potent and tolerable, Seedhouse said in the Monday upgrade note, citing his conversations with investors and physicians. This conviction has increased after the AASLD meeting, the analyst said. Alanine aminotransferase, an enzyme found in liver and kidney cells that is indicative of liver damage, transiently increased from the baseline within the first week of the study and subsequently declined, Seedhouse said.
- Thomson Reuters StreetEvents•28 days ago
Edited Transcript of VKTX earnings conference call or presentation 7-Nov-18 9:30pm GMT
Q3 2018 Viking Therapeutics Inc Earnings Call
- ACCESSWIRE•29 days ago
4 Healthcare Stocks To Watch On Wednesday
CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / Healthcare demand is increasing as an aging population continues to drive new healthcare market growth. The connection between healthcare goods and services is less tied to the economy compared to other sectors, and that could make healthcare stocks the place where investors will look for a hedge as the broader markets see increasing volatility. According to Bureau of Labor Statistics data*, the fastest-growing sectors include healthcare support occupations (23.2% increase from 2016-2026) and healthcare practitioners and technical occupations (15.2%), which entail home health aides, physician assistants and nurse practitioners, among other positions.
- Motley Fool•29 days ago
Better NASH Stock: Madrigal Pharmaceuticals, Inc. vs. Viking Therapeutics, Inc.
Positive results for similar candidates recently boosted both of these biotech stocks, but which is the better pick right now?
- ACCESSWIRE•29 days ago
Today’s Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Shares of EyeGate exploded on Tuesday on tremendous volume after reporting third quarter financial results. Shares of Viking Therapeutics were little changed ...
- TheStreet.com•last month
Viking Therapeutics Shows How Quickly This Market Can Turn
Market players are understandably very nervous about this market lately and that helped to cause the initial market strength to be sold quickly. bounced back after it breached its 200-day simple moving average and Larry Kudlow appeared on CNBC with some optimistic comments about a potential deal with China. The indices are now at intraday highs, breadth has moved to 4-3 positive and there is some bounce action.
- Zacks Small Cap Research•last month
VKTX: Phase 2 Data for VK2809 Presented at AASLD…
The Phase 2 trial was a randomized, double blind, placebo controlled study where patients were treated once daily or every other day with 10 mg VK2809 or once daily with placebo for 12 weeks followed by four weeks off drug. While the primary endpoint of the study was change in LDL cholesterol, the most important endpoints were the secondary ones related to NAFLD and nonalcoholic steatohepatitis (NASH) that evaluated changes in liver fat content, inflammatory markers, and histological changes.
- Benzinga•last month
Why Viking Therapeutics Shares Are Finding Renewed Buying Interest
Viking Therapeutics Inc (NASDAQ: VKTX) shares — which cooled off following an 87-percent jump Sept. 18 in reaction to positive top-line results from the mid-stage trial of VK2809 — were experiencing the return of upward momentum Tuesday. The company made a late-breaking oral presentation at the Liver Meeting 2018, the annual meeting of the American Association for the Study of Liver Diseases held in San Francisco. The top-line results of the study achieved the primary endpoint, Viking said: statistically significant reductions in LDL-C relative to a placebo following 12 weeks of treatment.
- ACCESSWIRE•last month
4 Stocks To Watch As Healthcare Technology Industry Is Expecting Rapid Growth Through 2025
CORAL GABLES, FL / ACCESSWIRE / November 13, 2018 / The U.S. patient engagement solutions market size is anticipated to reach $12.3 billion by 2025, expanding at a CAGR of 19.5% over the forecast period according to reports from Research And Markets*. With the volatility in today's market, many investors have turned to biotechnology and healthcare stocks as a safe haven from the broader market activity. Furthermore, the new age of technology and aging population unable to frequently visit a physical doctor's office has created a larger demand for technology intervention within the healthcare industry.
- Motley Fool•last month
Why Viking Therapeutics Stock Is Bolting Higher Today
Viking's latest NASH data suggest the company could be on to something special.
- PR Newswire•last month
Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver Meeting® 2018
Study Achieves Primary Endpoint, Demonstrating Statistically Significant LDL-C Reductions in Patients Receiving VK2809 at Week 12 67% of VK2809-Treated Patients Experienced ≥ 50% Reduction in Liver Fat ...
Motley Fool•last monthLigand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript
LGND earnings call for the period ending September 30, 2018.
- PR Newswire•last month
Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - Announced Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol ...
- Motley Fool•last month
Why Viking Therapeutics Stock Sank in October
The biotech's stock took a step back last month due to an industrywide downturn.
- PR Newswire•last month
Viking Therapeutics to Report Financial Results for Third Quarter 2018 on November 7, 2018
The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, November 7, 2018. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until November 14, 2018 by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering conference ID # 10125870. Those interested in listening to the conference call live via the internet may do so by visiting the Investor Relations section of Viking's website at www.vikingtherapeutics.com. An archive of the webcast will be available for 30 days on the company's website at www.vikingtherapeutics.com.
- Motley Fool•2 months ago
Where Will Gilead Sciences, Inc. Be in 5 Years?
Gilead's ongoing leadership churn could bring a new focus to the company.
- Motley Fool•2 months ago
3 Top Stocks Under $20
Looking for a few good low-priced stocks? Here are some picks you probably haven't considered.
- TheStreet.com•2 months ago
CAT Stock Gets Thrown Into the Dumpster
It is a sea of red out there with breadth hitting close to 6 to 1 negative and over 1000 stocks hitting new 12-month lows. took out the recent lows and is now back to levels it hit in early April. The S&P 500 also broke the October lows but has a little support at the late June levels.
- Yahoo Finance Video•last month
Stocks on the move: higher transportation and raw material cost clash with Home Depot's profitability
Yahoo Finance's Julie Hyman highlights today's stocks on the move in midday trading.
